Startup Spotlight: How Katalyze AI Transforms Biomanufacturing Data

Welcome to Snowflake’s Startup Spotlight, where we ask startup founders about the problems they’re solving, the apps they’re building and the lessons they’ve learned during their startup journey. In this edition, meet Reza Farahani, Co-Founder and CEO of Katalyze AI, and see how Katalyze AI transforms unstructured biomanufacturing documentation into searchable, structured data to optimize pharmaceutical production and accelerate time to market.

Who are you?

I’m Reza Farahani, Co-Founder and CEO of Katalyze AI. I’m a serial entrepreneur with a background in engineering, AI and data science consulting, and I’ve spent over a decade applying AI and machine learning to optimize complex workflows across various industries and sectors. 

What inspires you as a founder?

I am driven by the potential of AI to reshape biomanufacturing. The life sciences industry is driving innovations that feel like they belong in 2070, yet some of its manual, fragmented processes seem like they’re still stuck in the 1950s.

Bridging the gap between cutting-edge AI and the stringent operational realities of pharmaceutical production excites me. I see AI as a precision tool that can ultimately make life-saving products more accessible and cost effective.

What drove you to start Katalyze AI?

My motivation was realizing that manufacturing inefficiencies are the real bottlenecks preventing life-saving therapies from reaching patients. Diseases such as tuberculosis still claim millions of lives, not due to a lack of cures but because of inefficient, inconsistent production processes. I saw an opportunity to use AI to transform manufacturing so that therapies can be produced efficiently, consistently and at scale.

My vision with Katalyze AI is to unlock the full potential of biomanufacturing by addressing the “unsexy” but mission-critical challenges. These include optimizing raw material variability, automating documentation and scaling biologics production. Biopharma manufacturing isn’t just about mixing ingredients; it’s about consistently producing complex molecules with 20,000+ atoms, under precise conditions and at scale. That’s where AI becomes transformative, and that’s the future we’re building at Katalyze AI.

Biopharma manufacturing is a complex process. How did you identify a specific problem to tackle?

We are targeting one of the biggest hidden bottlenecks in biomanufacturing: the lack of structured, accessible data in production processes. Unstructured documentation can include batch records, deviation reports and quality logs. This slows down decision-making, introduces human error and makes it nearly impossible to leverage advanced analytics for process optimization.

Our team understands the challenge firsthand: We have experts from top consulting companies, major pharmaceutical companies, data companies and prestigious universities bringing their deep technical and industry knowledge to the problem. And that led us to design Digityze AI, our AI-powered document intelligence platform, to digitize and structure critical manufacturing data, enabling real-time searchability, automated reporting and advanced analytics.

How does the Snowflake Native App Framework enable you to push the envelope in your industry? 

By building Digityze AI as a Snowflake Native App, we’ve enabled seamless, secure and scalable document intelligence that operates directly within our customers’ Snowflake environments, reducing data silos, security concerns and integration friction.

Instead of relying on slow, manual data extraction processes, pharma manufacturers can now quickly search, apply AI-powered analytics and automate regulatory workflows. 

This unlocks end-to-end process visibility, allowing biopharma companies to accelerate production timelines, reduce waste and improve batch yields with data-driven precision. It was previously impossible at scale.

What impact has the Snowflake Native App Framework had on Katalyze AI's growth strategy?

Snowflake’s global GTM exposure is a game-changer. Biopharmaceutical manufacturing operates in one of the most data-sensitive and highly regulated industries, where security, compliance and operational reliability are nonnegotiable. By deploying Digityze AI as a Snowflake Native App, we gain immediate access to Snowflake’s 10,000+ enterprise customers, including some of the largest pharmaceutical and biotech manufacturers in the world.

This has transformed our go-to-market strategy in three key ways. The exposure offers us frictionless expansion into regulated markets because Snowflake is already embedded in top pharmaceutical firms. It also gives us instant enterprise-grade scalability since we can onboard new customers instantly. And Snowflake’s network of data leaders gives us direct access to decision makers through Snowflake’s existing relationships and GTM initiatives. 

What lessons have you learned as Katalyze AI has grown?

In the early days, we assumed that the impact of AI on biomanufacturing efficiency (for example, 8% yield gains in 10 weeks) would immediately drive adoption. But large pharmaceutical companies have entrenched processes, strict compliance requirements and complex stakeholder environments.

If I could go back, I’d focus earlier on embedding within industry ecosystems, like partnering with platforms like Snowflake and Veeva, aligning with regulatory and quality control teams, and ensuring that our AI models fit seamlessly into existing operational workflows. This approach has proven far more effective in driving adoption at scale.

What's the most valuable piece of advice you got about how to run a startup?

One of the best pieces of advice I received came from a mentor during my time at Boston Consulting Group (BCG): “Don’t build technology — solve a mission-critical problem.”

It’s easy to get caught up in the excitement of AI and data science, but at the end of the day, enterprise adoption depends on whether you’re addressing an urgent, high-value pain point. For Katalyze AI, that pain point is the inefficiency of unstructured documentation in biomanufacturing, which directly impacts yield, compliance and cost. Every feature we develop is measured against its ability to drive measurable impact in production outcomes, not just technical novelty.

AI is on everyone’s mind. As a founder and innovator, what is your perspective on the rapidly changing AI landscape? 

AI is entering a critical phase: moving from proof-of-concept hype to enterprise-wide operationalization. The most exciting and valuable AI/ML innovations are those that move from insights to automation, enable seamless enterprise integration and enhance explainability and regulatory compliance. That’s why building on Snowflake is critical. It enables AI insights to be generated and applied within a secure, compliant data environment, eliminating the friction of data movement.

On the concerning side, the biggest challenge is over-reliance on AI without industry-specific expertise. Many AI startups focus on generalized automation, but in biomanufacturing, domain knowledge is just as important as the model itself. That’s why our approach combines deep pharma expertise with AI-driven decision-making, ensuring that every insight is actionable, trustworthy and compliant.

The future of AI in biopharma isn’t just about better data, it’s about intelligent automation that directly impacts production efficiency, cost and time to market. That’s exactly what Katalyze AI is building.

Learn more about how Katalyze AI is transforming biomanufacturing at https://katalyzeai.com/, try the Digityze AI app on Snowflake Marketplace or read Farahani’s post on the Snowflake Builder Blog on Medium for technical details. If you’re a startup building on Snowflake, check out the Powered by Snowflake Startup Program for info on how Snowflake can support your goals.